Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11741MR)

This product GTTS-WQ11741MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11741MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14087MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ5389MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ7309MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ10635MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ7207MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ155MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ5046MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ6493MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW